Qimin Zhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Qimin Zhan has a total of 364 co-authors. Here are the top co-authors by number of shared publications:
Yongmei Song
12 shared publicationsMing Fu
State Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
11 shared publicationsWeimin Zhang
State Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
8 shared publications- Yongping Cui
Translational Medicine Research Center, Shanxi Medical University, Taiyuan, Shanxi, China
7 shared publications Bin Song
6 shared publicationsBin Yang
6 shared publications
Latest Publications
- Open Access
- 1 September 2020
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 107 (3) , 579
Genomic Analyses Reveal Mutational Signatures and Frequently Altered Genes in Esophageal Squamous Cell Carcinoma
- 1 September 2020
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 107 (3) , 579
Open AccessGenomic Analyses Reveal Mutational Signatures and Frequently Altered Genes in Esophageal Squamous Cell Carcinoma
- Open Access
- 1 August 2020
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 107 (2) , 375
Genomic Analyses Reveal Mutational Signatures and Frequently Altered Genes in Esophageal Squamous Cell Carcinoma
- 1 August 2020
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 107 (2) , 375
Open AccessGenomic Analyses Reveal Mutational Signatures and Frequently Altered Genes in Esophageal Squamous Cell Carcinoma
- Open Access
- 1 January 2018
- Published by China Anti-cancer Association in Cancer Biology & Medicine
- Vol. 15 (4) , 400-+
Flotillin1 promotes EMT of human small cell lung cancer via TGF-β signaling pathway
Flotillin1 promotes EMT of human small cell lung cancer via TGF-β signaling pathway
- 1 January 2018
- Published by China Anti-cancer Association in Cancer Biology & Medicine
- Vol. 15 (4) , 400-+
Open AccessFlotillin1 promotes EMT of human small cell lung cancer via TGF-β signaling pathway
Flotillin1 promotes EMT of human small cell lung cancer via TGF-β signaling pathway
- 1 November 2017
- Published by Elsevier in Science Bulletin
- Vol. 62 (21) , 1445-1454
Transcriptional activation of Nlp by estrogen-ERα in breast cancer
- 1 November 2017
- Published by Elsevier in Science Bulletin
- Vol. 62 (21) , 1445-1454
Transcriptional activation of Nlp by estrogen-ERα in breast cancer
- 1 August 2017
- Published by Elsevier in Experimental Cell Research
- Vol. 357 (1) , 51-58
Downregulation of β-arrestin 1 suppresses glioblastoma cell malignant progression vis inhibition of Src signaling
- 1 August 2017
- Published by Elsevier in Experimental Cell Research
- Vol. 357 (1) , 51-58
Downregulation of β-arrestin 1 suppresses glioblastoma cell malignant progression vis inhibition of Src signaling
- Open Access
- 4 October 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (46) , 74872-74885
Kindlin-2 interacts with β-catenin and YB-1 to enhanceEGFRtranscription during glioma progression
Kindlin-2 interacts with β-catenin and YB-1 to enhance EGFR transcription during glioma progression
- 4 October 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (46) , 74872-74885
Open AccessKindlin-2 interacts with β-catenin and YB-1 to enhanceEGFRtranscription during glioma progression
Kindlin-2 interacts with β-catenin and YB-1 to enhance EGFR transcription during glioma progression
- Open Access
- 27 July 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (34) , 55555-55571
Targeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling
Https://doi.org/10.18632/oncotarget.10864 Tian Lan, Zitong Zhao, Yanming Qu, Mingshan Zhang, Haoran Wang, Zhihua Zhang, Wei Zhou, Xinyi Fan, Chunjiang Yu, Qimin Zhan, Yongmei Song
- 27 July 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (34) , 55555-55571
Open AccessTargeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling
Https://doi.org/10.18632/oncotarget.10864 Tian Lan, Zitong Zhao, Yanming Qu, Mingshan Zhang, Haoran Wang, Zhihua Zhang, Wei Zhou, Xinyi Fan, Chunjiang Yu, Qimin Zhan, Yongmei Song
- 1 April 2016
- Published by Elsevier in Cancer Letters
- Vol. 373 (2) , 214-221
Mitotic regulator Nlp interacts with XPA/ERCC1 complexes and regulates nucleotide excision repair (NER) in response to UV radiation
- 1 April 2016
- Published by Elsevier in Cancer Letters
- Vol. 373 (2) , 214-221
Mitotic regulator Nlp interacts with XPA/ERCC1 complexes and regulates nucleotide excision repair (NER) in response to UV radiation
- Open Access
- 1 February 2016
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 98 (2) , 256-274
Whole-Genome Sequencing Reveals Diverse Models of Structural Variations in Esophageal Squamous Cell Carcinoma
- 1 February 2016
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 98 (2) , 256-274
Open AccessWhole-Genome Sequencing Reveals Diverse Models of Structural Variations in Esophageal Squamous Cell Carcinoma
- Open Access
- 11 January 2016
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 5 (1) , 1
Genomic analyses reveal FAM84B and the NOTCH pathway are associated with the progression of esophageal squamous cell carcinoma
Background: Esophageal squamous cell carcinoma (ESCC) is the sixth most lethal cancer worldwide and the fourth most lethal cancer in China. Genomic characterization of tumors, particularly those of different stages, is likely to reveal additional oncogenic mechanisms. Although copy number alterations and somatic point mutations associated with the development of ESCC have been identified by array-based technologies and genome-wide studies, the genomic characterization of ESCCs from different stages of the disease has not been explored. Here, we have performed either whole-genome sequencing or whole-exome sequencing on 51 stage I and 53 stage III ESCC patients to characterize the genomic alterations that occur during the various clinical stages of ESCC, and further validated these changes in 36 atypical hyperplasia samples. Results: Recurrent somatic amplifications at 8q were found to be enriched in stage I tumors and the deletions of 4p-q and 5q were particularly identified in stage III tumors. In particular, the FAM84B gene was amplified and overexpressed in preclinical and ESCC tumors. Knockdown of FAM84B in ESCC cell lines significantly reduced in vitro cell growth, migration and invasion. Although the cancer-associated genes TP53, PIK3CA, CDKN2A and their pathways showed no significant difference between stage I and stage III tumors, we identified and validated a prevalence of mutations in NOTCH1 and in the NOTCH pathway that indicate that they are involved in the preclinical and early stages of ESCC. Conclusions: Our results suggest that FAM84B and the NOTCH pathway are involved in the progression of ESCC and may be potential diagnostic targets for ESCC susceptibility.
- 11 January 2016
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 5 (1) , 1
Open AccessGenomic analyses reveal FAM84B and the NOTCH pathway are associated with the progression of esophageal squamous cell carcinoma
Background: Esophageal squamous cell carcinoma (ESCC) is the sixth most lethal cancer worldwide and the fourth most lethal cancer in China. Genomic characterization of tumors, particularly those of different stages, is likely to reveal additional oncogenic mechanisms. Although copy number alterations and somatic point mutations associated with the development of ESCC have been identified by array-based technologies and genome-wide studies, the genomic characterization of ESCCs from different stages of the disease has not been explored. Here, we have performed either whole-genome sequencing or whole-exome sequencing on 51 stage I and 53 stage III ESCC patients to characterize the genomic alterations that occur during the various clinical stages of ESCC, and further validated these changes in 36 atypical hyperplasia samples. Results: Recurrent somatic amplifications at 8q were found to be enriched in stage I tumors and the deletions of 4p-q and 5q were particularly identified in stage III tumors. In particular, the FAM84B gene was amplified and overexpressed in preclinical and ESCC tumors. Knockdown of FAM84B in ESCC cell lines significantly reduced in vitro cell growth, migration and invasion. Although the cancer-associated genes TP53, PIK3CA, CDKN2A and their pathways showed no significant difference between stage I and stage III tumors, we identified and validated a prevalence of mutations in NOTCH1 and in the NOTCH pathway that indicate that they are involved in the preclinical and early stages of ESCC. Conclusions: Our results suggest that FAM84B and the NOTCH pathway are involved in the progression of ESCC and may be potential diagnostic targets for ESCC susceptibility.